Blood and Marrow Transplant

Sickle Cell Disease: Increasing Shared Decision-Making and Clinical Trial Participation (NMDP/Be The Match)
September 12, 2018
Description: Join us for a free continuing education webinar on September 12, 2018 at 12:00 – 1:15 p.m. CDT. Lakshmanan Krishnamurti, MD, from Children’s Healthcare of Atlanta/Emory University, will discuss new insights on shared decision-making to address barriers to clinical trial participation among individuals affected by sickle cell disease (SCD). Lensa Idossa, MPH, from NMDP/Be The Match, will summarize initiatives of SCD patient advocacy organizations to help increase patient participation in clinical trials. See full webinar details for more information. This program is provided by the NMDP/Be The Match and the Sickle Cell Disease Association of America, Inc. Continuing education credits are available for nurses, social workers and laboratory professionals. Register Now.

Patient-Centered Care Coordination in HCT (FACT), September 20, 2017
Description: This webinar will be on September 20, 2017, at 11:00 ET. Nandita Khera, MD, MPH, of the Mayo Clinic Arizona, and Patricia Martin, RN, BSN, of WellPoint Inc., will explain why care coordination is important for the HCT community. Presenters will highlight the benefits and metrics of effectiveness of care coordination, introduce the care coordination toolkit, and identify the key components of the proposed framework.

Tiempo, Esfuerzo y Recursos para la Acreditacion de FACT-JACIE (FACT-JACIE), August 24, 2017
Description: Este seminario consiste en breves presentaciones de tres programas de terapia celular acreditados en América Latina y España en relación con el tiempo, el esfuerzo y los recursos que utilizaron para obtener la acreditación FACT.
María José Jiménez Lorenzo de Hospital Germans Trias i Pujol-Institut Català d'Oncologia (ICO) Servicio de Hematología de Badalona, Barcelona, Cesar Homero Hospital Universitario Gutiérrez Aguirre Universidad Autónoma de Nuevo, México, y Andrea Kondo de Cordón Banco de Sangre Albert Einstein Hospital explican cómo se prepararon para el proceso de acreditación.

Lecture on medical basics of haematopoietic stem cell transplantation: indication for transplantation; patient work-up; post-transplant complications; late effects and monitoring (WMDA/EBMT)
Description: Part of the WMDA/EMBT Search Coordinator Certificate Programme basic level, a lecture given by Bronwen Shaw, MD, PhD explaining the medical basics on haematopoietic stem cell transplantation.

Extracorporeal Photopheresis for BOS after Lung Tx (ASFA)
Description: Dr. George Despotis of Washington University School of Medicine presents Extracorporeal Photopheresis for BOS after Lung Tx: Overview of ECP/WUSM experience and CMS approved Multicenter Registry project.

Hematopoietic Stem Cell Transplantation: A Primer (ASFA)
Description: Following the webinar, participants should be able to list indications for hematopoietic stem cell transplant; explain methods of stem cell mobilization; and describe the immunological consequences of HSCT.

Sickle Cell Disease: Treatment Options including BMT, Care and Support (NMDP/Be The Match)
Description: This on-demand activity provides information on the benefits and risks of deciding to pursue transplantation as a treatment option for patients with SCD. You will learn about the advances in allogeneic transplantation for patients with SCD and the importance of shared decision making among this patient population.

Coping with Chronic GVHD: Resources for Health Professionals (NMDP/Be The Match)
Description: Quality of live is composed of related domains including: physical, emotional, social, and role functioning, as well as a person's overall evaluation of his or her well-being and ability to function. The understanding of the etiology of and best treatments for cGVHD is limited; therefore, attention to supportive care and QOL is critical when providing care for people with cGVHD. This free on-demand webinar will explore the impact of cGVHD on QOL and explore the goals of the Chronic GVHD Consortium and its implications in caring for patients affected by cGVHD.

Blood or Marrow Transplant for Myelodysplastic Syndromes: Treatment Options and Psychosocial Support (NMDP/Be The Match)
Description: With the development of reduced-intensity conditioning regimens making transplant more feasible for older patients, more patients with MDS are now eligible for a blood or marrow transplant (BMT), the only potentially curative treatment option. This free on-demand webinar addresses advances in transplant options for patients with MDS, benefits of timely transplant consultation and quality of life considerations.

Histocompatibility Testing in HCT: The Impact on Clinical Outcomes Driving Test Selections (ASHI), September 21, 2016
Description: Marcelo Fernández-Viña, PhD, HLA Consultant in the HLA Laboratory at Stanford Medicine Blood and Marrow Transplant Program, gives an overview of histocompatibility testing in HCT and the impact on clinical outcomes driving test selections.

Addressing clinical challenges in AML to optimize treatment plans (NMDP/Be The Match) September 29, October 20, & November 17, 2016
Description: In this 3 part on-demand CME activity, panelists will use case studies to present the latest research on three key areas affecting clinical decision-making for patients with acute myelogenous leukemia (AML): risk stratification using patient cytogenetic and molecular markers, optimal timing of treatments for patients in first remission, and exploring treatment options for older patients.

Improving Sickle Cell Disease Outcomes: Treatment decision making, curative therapies and overcoming barriers to care(NMDP/Be The Match), December 2, 2016
Description: Caring for patients with SCD is complex due to many factors, including the unpredictable course of the disease. Treatment decisions need to balance the morbidity and mortality that increases into adulthood with the potential risks and benefits of each treatment option. Additionally, barriers in access to care can affect quality of life for these patients throughout their disease course. This enduring activity brings together critical perspectives to address these needs. Attendees will learn in-depth data on the latest treatment outcomes, upcoming clinical trials and new insights into shared decision-making between providers and patients.

BMT Training Programs(ASBMT)
Description: ASBMT compiles information on programs offering a blood and marrow fellowship (BMT) or hematology/oncology fellowship with strong BMT emphasis. This listing also includes programs offering clinical electives for students, residents, and fellows.

Chronic Graft Versus Host Disease Practice Improvement Module(ASBMT)
Description: The Chronic Graft versus Host Disease module is based on the NIH Consensus Development Project (Filipovich et al. Biology of Blood and Marrow Transplantation 2005; 11:945-955) and includes five measures for the management of disease. Available only to ASBMT members, and is free of charge.

Infection Control Practice Improvement Module(ASBMT)
Description: Six measures are included in the Infection Control module that is based on the Guidelines for Preventing Infectious Complications (Tomblyn et al. Biology of Blood Marrow Transplant 2006; 15:1143-1238). Available only to ASBMT members, and is free of charge.

Pediatric Survivors After HCT(NMDP/Be The Match)
Description: Following hematopoietic cell transplantation (HCT), pediatric recipients face a high incidence of late effects, underscoring the need for long-term monitoring and early detection. To optimize the long-term care for patients with malignant and non-malignant diseases, this case-based activity explores post-autologous and allogeneic HCT screening recommendations, including: risk factors associated with exposures and late effects, screening and assessment guidelines, and vaccination schedules.

AML and MDS in older adults(NMDP/Be The Match)
Description: Explore practical applications of classification and research data to compare treatment choices for older AML and MDS patients, including: How diagnostic testing has changed the timing of therapeutic choices and if age should be considered; Applying data to mitigate risk and optimize the benefit among new drugs, transplantation, and combination approaches; What coverage options are available for Medicare-eligible patients.

Decision to Pursue HCT for Sickle Cell Disease(NMDP/Be The Match)
Description: This program provides information on the benefits and risks of deciding to pursue transplantation as a treatment option for patients with SCD. You will learn about the advances in allogeneic transplantation for patients with SCD and the importance of shared decision making among this patient population.

Coping with Chronic GVHD of the Skin and Deeper Tissues: Resources for Health Professionals (NMDP/Be The Match)
Description: Chronic graft-versus-host disease (cGVHD) is a major complication of allogeneic blood and marrow transplantation (BMT). One out of every five patients treated for GVHD is diagnosed with chronic GVHD of the skin and deeper tissues.2 There are many variables that influence the risk of cGVHD, so it’s important to understand the etiology and best treatments available when caring for BMT patients. In this on-demand webinar, speakers will address the signs, symptoms and diagnostic criteria for cGVHD of the skin and deeper tissues. They will also discuss current advances in research and share ways for patients to cope with the impact on quality of life.

Acute Myeloid Leukemia (AML): Treatment Options, including BMT, Care and Support (NMDP/Be The Match)
Description: Timely access to information on treatment options can empower patients and their families to actively participate in their treatment plan. Dr. Gail Roboz and Dr. Sergio address the risks and benefits of treatment options for patients with AML; how cytogenetics can help to inform clinicians' treatment decisions; and the impact of well-timed referral for blood and marrow transplantation (BMT) on outcomes for patients with high-risk AML.

Caring for HCT Survivors: A Review of the 2012 Guidelines to Monitor Late Effects (NMDP/Be The Match)
Description: Join Dr. Navneet Majhail as he reviews key updates from the 2012 publication, Recommended screening and preventive practices for long-term survivors after HCT1. This 45-minute webinar will help you understand the updated guidelines for long term follow-up care of HCT survivors, provide ideas for implementing these guidelines into your practice, and review free resources to help you share these recommendations.

Four-Part Series: Management of Advanced Non-Hodgkin Lymphomas (NMDP/Be the Match)
Description: This series provides an overview of four different disease subtypes of non-Hodgkin lymphoma where transplantation is an option for treatment. The lectures discuss choices for first-line and second-line treatment and options for the patient who relapses or is refractory to current treatment.

Results of the BMT CTN Protocol (0201) PBSC versus Marrow Study (NMDP/Be the Match)
Description: Results of the BMT CTN Protocol 0201 PBSC versus Marrow study were presented during the Plenary session at the 2011 American Society of Hematology (ASH) Annual Meeting in San Diego. This webinar recounts this presentation on the randomized, multicenter, phase III trial that compared survival rates for patients receiving PBSC with patients receiving bone marrow.

Decision to Pursue HCT for Sickle Cell Disease (NMDP/Be the Match)
Description: This program provides information on the benefits and risks of deciding to pursue transplantation as a treatment option for patients with SCD. You will learn about the advances in allogeneic transplantation for patients with SCD and the importance of shared decision making among this patient population.

BMT Curriculum (NMDP/Be the Match)
Description: To give you exposure to the exciting biology and clinical practice of blood and marrow transplant, (BMT) leading transplant physicians have come together to develop 16 didactic curriculum modules and several testimonial videos on "why I chose BMT". These modules provide the fascinating history and future of BMT, fundamentals of the science behind transplant, state-of-the-field disease summaries, immunobiology and donor selection, early and late effects and more. One module describes how to mold a career in BMT.These modules can be used for the didactic portion of a BMT elective rotation for medical students and fellows. Other clinicians in hematology/oncology may also find them helpful.

HLA Matching Guidelines for Selecting Unrelated Donors and CBUs for HCT (NMDP/Be the Match)
Description: Learn practical applications of the recently updated matching criteria for selection of marrow, PBSC, and cord blood unit (CBU) cell sources. Participants will gain perspective on which pre- and post-transplant factors have the most impact on outcomes, optimal match criteria for selecting marrow, PBSC, and CBUs, and the non-HLA factors that affect cell source decisions. Participants will also learn about ongoing research trials and impact on donor and cord selections and timing.

Part I – Implementing Changes from the 6th Edition FACT Cellular Therapy Standards: Clinical and Collection Requirements (FACT), February 25, 2015

Description: This webinar was live on February 25, 2015. Dr. Philip McCarthy provided specific examples for transplant programs and collection facilities to effectively implement significant changes required by the 6th Edition of Standards.

FACT 6th Edition Cellular Therapy Standards Pharmacy Requirements(FACT), October 28, 2015
Description: This webinar was live on October 28, 2015. Katie Boyd, PharmD, from Samford University; Tippu Khan, PharmD, from University of North Carolina Hospitals and chair of the ASBMT Pharmacy Special Interest Group; and Connie Sizemore, PharmD, Lead Clinical Pharmacy Specialist at Blood and Marrow Transplant Group of Georgia at Northside Hospital explained the rationale for adding pharmacy requirements to the FACT-JACIE Standards and provided examples for how to comply with them.

International Hematology Club Meeting: A Focus on Lymphoid Diseases(IHC, November 6-7, 2015 in Paris, France)
Description: This meeting will share up-to-date information and provide a unique opportunity for world class leaders in the field to discuss vital and contentious issues in hematology. This thought-provoking dialogue will address the most challenging current academic clinical and technological questions and will provide clinicians with state-of-the-art recommendations regarding patient care. Cutting-edge data related to disease pathophysiology, rare entities, multiple myeloma, chronic lymphocytic leukemia and lymphoma therapy will be included.

Using CIBMTR Data to Determine and Evaluate Clinical Outcomes(FACT), June 22, 2016
Description: This webinar was live on June 22, 2016. Stephen Spellman, MBS, is the Director of the CIBMTR Immunobiology and Observational Research Programs and serves as a Scientific Director for the Immunobiology and Graft Versus Host Disease Working Committees of the CIBMTR. He gave an overview of how CIBMTR data is used to determine outcomes, and how Clinical Programs can use additional data to further evaluate outcomes and improve.